Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
huCART19-IL18-CD428z Cells for HIV Patients With CD19+ Cancers
NCT07891468Phase 1Not yet recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jan 2027
- Primary completion
- Dec 2042
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of huCART19-IL18-CD428z in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL) and 1 more, sponsored by University of Pennsylvania. Primary endpoint: Safety at 15 years. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
huCART19-IL18-CD428z
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)acute lymphoblastic leukemia (ALL)Richter's transformation (RT)
Beyond the preview
Go deeper on NCT07891468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07891468.